Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q3 FY2024 Earnings Presentation
35 slides from Syngene International's earnings presentation, Jan 25, 2024
Slide 1: Cover letter to stock exchanges
Ref: Syn/CS/SE/IP/2023-24/Jan/09 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com January 25, 2024 T
Slide 2: Investor Presentation January 2024
Investor Presentation January 2024
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward‐looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward‐looking statements
Slide 4: Contents
Contents 1 Operating Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Appendix Putting Science to Work 3
Slide 5: Operating Highlights
1 Operating Highlights Syngene
Slide 6: Q3 and 9 Months FY24 performance
Q3 and 9 Months FY24 performance Operating Highlights Q3 Financial Highlights • The third quarter was underpinned by positive performance in Development and Total Revenue: Rs 8,828 Mn Manufacturing Services as well as in the Dedicated Centers. Performance in Revenue from Operations: 9% YoY Reported
Slide 7: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 8: Partner in innovation: Putting science to work
Partner in innovation: #Putting science to work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more Established track record in solutions across pharmaceuticals, biotec
Slide 9: Our journey so far
Our journey so far 2019 – 2024 Continued investments and Globalization and strategic collaboration • Expanded into formulations development growth • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expanded collaboration with BMS, biological therapeutic molecules Amgen and Zoetis •
Slide 10: Key facts and figures
Key facts and figures 400+ 13 out of top 15 400+ World class infrastructure active clients pharma companies are patents 3 campuses in Bangalore, Hyderabad and Mangalore clients held with clients qualified to meet international standards Rs. 45,589 Mn Rs. 32,638 Mn Rs. 4,644 Mn ~8,500+ headcount 75%
Slide 11: Our strategic priorities
Our strategic priorities Research: Discovery Research: Dedicated Services Centers Operational Excellence Provide end‐to‐end therapeutic Continue to strengthen our existing Focus on customer delivery through discovery capabilities including partnerships with Amgen, Bristol operational excellence diff
Slide 12: Our broad capabilities, spanning the value chain
Our broad capabilities, spanning the value chain, facilitate integration and captures additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability across
Slide 13: Sustained investment in skilled workforce and world class infrastructure
Sustained investment in skilled workforce and world class infrastructure: a catalyst for expanded client base and strong revenue growth Constantly Growing Increasing High expanding Growing Infrastruc Increasing Client Strong revenue Revenue skilled infrastructure ture clientBase base growth Growth w
Slide 14: Strategic investments augment cash flows and EPS
Strategic investments augment cash flows and EPS, driving consistent shareholder returns Growing Increasing Increasing Increasing High High Cash Improving EPS Infrastruc operating cash Client Flow market Revenue Soaring ture flow Base Growth Market capitalization Capitaliza tion EPS doubled since *F
Slide 15: Syngene strengths
3 Syngene strengths
Slide 16: Syngene strengths
Syngene strengths A global scale CRO/CDMO Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track rec
Slide 17: Our end-to-end platform: one-stop-shop for discovery, development and manufacturing
Our end‐to‐end platform enables us to be a 'one‐stop‐shop' for discovery, development and manufacturing (small molecules and biologics) Discovery Development Manufacturing Chemistry Drug Substance Clinical Supplies Small Drug Product Molecules Biology Biologics Integrated Drug Substance – Drug Produ
Slide 18: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers ~8,500+ Inspiring technical excellence and providing opportunities to grow total headcount Nurturing young • Syngene Training Academy offers new graduate recruits a six‐month extended induction to help 6000+ scientists delivering talent and th
Slide 19: Extended state-of-the-art infrastructure and new capabilities
Extended our state‐of‐the‐art infrastructure & new capabilities in different locations within India to meet our strategic partners needs… HQ campus at Bangalore, India 90 Acres (3,64,217 sq. mt) where most of Syngene’s capabilities are housed today Fully functional R&D Centre at Genome Valley, Hyder
Slide 20: Successful collaboration models
We currently operate a range of successful collaboration models Dedicated R&D Labs Full time equivalent (FTE) Fee For service (FFS) Risk‐reward • Dedicated scientific resources • Dedicated scientific and support • Flexible, on‐demand resources with • Rewards based on clearly defined, selected from p
Slide 21: Experience spans multiple industry segments and global partners
Our experience spans multiple industry segments and partners us with global leaders across the world… Large & Mid‐Sized Emerging Chemicals/ BioPharma BioPharma (EBP) Animal Health AgroChem CPG Polymers Putting Science to Work 20
Slide 22: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded in operations driven by Focused execution through strong Project certified operational leaders Management Six Sigma Black Belt certified staff in each Structured program management for executing client service line and
Slide 23: Digitization and automation through Lab 4.0 strategy
We are harnessing digitization and automation through our Lab 4.0 strategy At Syngene, we have adopted Lab 4.0, deploying technology for compliance, Certification as per ISO 13485:2016, ISO/IEC as an optimizer and as an augmenter 27001 and ISO 9001:2015 requirements Online management of specificatio
Slide 24: Committed to safety and sustainability
Committed to safety and sustainability Committed to environmental protection • Committed to Science‐based targets for greenhouse gases Safety is our first priority • 90+% of total hazardous and • Accredited with ISO 45001:2018 non‐hazardous waste recycled for Occupational Health and • 75% of energy
Slide 25: International accreditations
International accreditations • USFDA,OHSAS 18001 • GLP, cGMP, AAALAC & CPCSEA Certified facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation • EMA and PMDA approved, AAALAC accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:201
Slide 26: Industry recognition for scientific capability and business excellence
We have consistently received industry recognition for our scientific capability and business excellence • CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma • CMO Leadership Award Winner 2020 ‐ under • CMO Leadership Award Champion 2022 ‐ Presented by Life Science Lea
Slide 27: Robust risk management framework
Robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk Every risk owner monitors and manages risks relevant to their area of responsibility Executive Committee (EC) Board of Directors(BOD) • Sign‐off on Enterprise Risk Framework annually
Slide 28: Financials
4 Financials
Slide 29: Q3FY24 financial highlights
Q3FY24 financial highlights YoY Particulars Q3 FY24 Q3 FY23 Q2 FY24 QoQ change change Revenue from operations 8,535 7,859 9% 9,101 ‐6% Other income 293 172 70% 216 35% Reported revenue 8,828 8,031 10% 9,317 ‐5% Balance Sheet Highlights Material costs 2,374 2,061 15% 2,672 ‐11% As on 31st December 20
Slide 30: 9MFY24 financial highlights
9MFY24 financial highlights Particulars 9M FY24 9M FY23 YoY change Revenue from operations 25,717 21,985 17% Other income 745 481 55% Reported revenue 26,462 22,466 18% Material costs 7,274 5,664 28% Staff costs 7,105 6,347 12% Other direct costs 805 835 ‐4% Other expenses 3,100 2,561 21% Foreign ex
Slide 31: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 32: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation‐led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.
Slide 33: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* NSE Ticker SYNGENE 0.8% BSE Ticker 539268 Promoter & Promoter Group Market Cap (Rs. Mn) 2,81,993 44.5% Public 54.8% % free‐float 45% ESOP Trust Free‐float market cap (Rs. Mn) 1,26,897 Share Outstanding (M
Slide 34: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene‐international‐limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G/ Suruchi Daga Sho
Slide 35: Thank you
Thank you © 2023 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Syngene International — Q3 FY2024 Earnings Presentation on 6ix